The Endoplasmic reticulum aminopeptidase I (ERAP1) trims peptides to their optimal size for binding to Major Histocompatibility Complex class I proteins. The natural polymorphism of this enzyme is associated with ankylosing spondylitis (AS) in epistasis with the major risk factor for this disease, HLA-B*27, suggesting a direct relationship between AS and HLA-B*27-bound peptides. Three polymorphisms that affect peptide trimming protect from AS: K528R, D575N/R725Q, and Q730E. We characterized and ranked the effects of each mutation, and their various combinations, by quantitative comparisons of the HLA-B*27 peptidomes from cells expressing distinct ERAP1 variants. Five features were examined: peptide length, N-terminal flanking residues, N-terminal residues of the natural ligands, internal sequences and affinity for B*27:05. Polymorphism at residue 528 showed the largest influence, affecting all five features regardless of peptide length. D575N/R725Q showed a much smaller effect. Yet, when co-occurring with K528R, it further decreased ERAP1 activity. Polymorphism at residue 730 showed a significant influence on peptide length, because of distinct effects on trimming of nonamers compared with longer peptides. Accordingly, multiple features were affected by the Q730E mutation in a length-dependent way. The alterations induced in the B*27:05 peptidome by natural ERAP1 variants with different K528R/Q730E combinations reflected separate and additive effects of both mutations. Thus, the influence of ERAP1 on HLA-B*27 is very diverse at the population level, because of the multiplicity and complexity of ERAP1 variants, and to the distinct effects of their co-occurring polymorphisms, leading to significant modulation of disease risk among HLA-B*27-positive individuals. Molecular & Cellular Proteomics 17: 10.1074/mcp.RA117.000565, 1308–1323, 2018.
rs10050860 may be accounted for by strong linkage disequi-
librium with a splice-altering variant, rs7063, influencing pro-
tein levels (19).

Multiple studies that analyzed the association of natural
ERAP1 haplotypes with AS, reviewed in (14), showed that one
or more of the Hap1–Hap3 haplotypes, all including the risk
polymorphisms at residues 528, 575, and 725, were associ-
ated with increased risk of AS, whereas Hap10, including the
protective polymorphisms at all three positions, was protec-
tive. In early genetic studies the Q730E polymorphism showed
one of the highest associations with AS, Q730 being the
risk variant (15, 20). These studies did not specifically
address the linkage disequilibrium among missense polymor-
phisms within the ERAP1 gene. A more recent fine mapping
study (21) restricted the AS susceptibility region of ERAP1 to
a relatively short span of DNA, including both the missense
SNPs rs30187 (K528R) and rs10050860 (D575N), but not
rs27044 (Q730E), raising the possibility that the latter might
not be directly involved in AS.

The epistatic association of ERAP1 with AS and other in-
flammatory diseases (22) suggests a pathogenetic role of
peptide processing, emphasizing the need to characterize
the effects of ERAP1 polymorphism on MHC-I bound pep-
tidomes. The issue is not simple because of the distinct
influence of individual polymorphisms on the enzymatic ac-
tivity of ERAP1 and the likely interplay of effects of these
changes in the natural ERAP1 haplotypes. This is suggested
by observations that the activity of a given ERAP1 variant is
the result of its combination of polymorphic residues
(23, 24). These studies pointed to the necessity of directly
defining the effect of natural ERAP1 haplotypes on the
HLA-B*27 peptidome in live cells with distinct ERAP1
backgrounds.

Two previous studies from our laboratory addressed this
issue (25, 26), demonstrating the significant influence of
disease-associated ERAP1 variants on the HLA-B*27 pepti-
dome. They also showed a dominant effect of the K528R
change over D575N/R725Q, in agreement with in vitro studies
showing that polymorphism at residue 528 is a major deter-
minant of ERAP1 activity (27–29). Yet, our earlier studies used
a relatively low-resolution peptidomic approach, which in-
volved the direct identification of a reduced number of pep-
tides, limiting statistical assessments and the detection of
effects on the peptidome to the very major ones. Moreover, in
the first of those studies (25), the presence of ERAP2 was not
fully considered. This enzyme trims basic and few other P1
residues (10, 22), is also involved in the processing of MHC-I
ligands (10, 30–32), is not expressed in at least 25% of

The abbreviations used are: MHC-I, Major Histocompatibility
Complex class I; AS, ankylosing spondylitis; E:S, enzyme/substrate;
IR, intensity ratio; L-AMC, Leu-7-amido-4-methyl-coumarine; mAb,
monoclonal antibody, P(-1), N-terminal flanking residue; P1, N-termi-
nal residue; SNP, single nucleotide polymorphism.

ERAP1 Polymorphism and the HLA-B*27 Peptidome

Thus, in the present study we undertook a systematic
and comprehensive analysis of the effects of AS-associated
ERAP1 polymorphism on the HLA-B*27 peptidome. We com-
pared the B*27:05 peptidomes from ERAP2-positive cells ex-
pressing distinct ERAP1 haplotypes by means of a homoge-
neous and high-resolution immunopeptidomic approach.
Through the identification of several thousands of peptides
from each cell line obtained in uniform conditions, we were
able to characterize ERAP1-dependent changes affecting
multiple features of the peptidome with high reliability and
statistical strength. By selecting cell lines with ERAP1 variants
showing different combinations of polymorphic residues, we
could assign distinct effects to individual disease-associated
changes, rank their relative contribution to shaping the HLA-
B*27 peptidome, and define the interactive effects among co-
occurring polymorphisms in the natural ERAP1 haplotypes.

MATERIALS AND METHODS

Cell Lines, and Western Blots—Four HLA-B*27:05-positive lym-
phoblastoid cell lines (LCL) were used in this study: LCL 6370 (HLA-
A*02, *68; B*27:05, *44; C*02, *07), LG2 (HLA-A*02, B*27:05, C*01),
P50 (HLA-A*23, *24; B*27:05, *14; C*02, *08) and C1R05 (B*27:05,
*35.03**), (C*04) (Table I). The latter is a transfectant line derived from
HY2.C1R cells, which are defective in their endogenous HLA-A, B
genes (36). The four cell lines are ERAP2-positive and express similar
levels of this enzyme (26, 35). They are homozygous at the ERAP1
locus and express distinct ERAP1 allotypes (26, 34). The cells were
cultured in RPMI 1640 medium with 10% fetal bovine serum (Biowest,
Nuaille, France), 25 mM HEPES buffer, 2 mML-glutamine, penicillin and
streptomycin. ME1 (IgG1), an anti-HLA-B*07/B*27/B*22 monoclonal
antibody (mAb) that recognizes HC/p2m/peptide complexes (37), was
used for immunopurification of HLA-B*27. Among the non-B*27 MHC-I
molecules expressed in the cell lines used in this study, ME1 is known
to have a weak cross-reaction only with HLA-B*14 (38, 39). Besides this
antibody, W6/32 (IgG2a), which recognizes a monomorphic determi-
nant of HLA-A,B,C molecules (40) was used in flow cytometry.

Western blotting was done and quantified as previously described
(25), using the mAbs 6H9, 3F5 (both from RD systems, Minneapolis,
MN), and GTU88 (Sigma) to reveal ERAP1, ERAP2 and α-tubulin,
respectively.

Flow Cytometry—About 2 × 10⁵ cells where washed twice with 200
μL of PBS, centrifuged at 1500 RPM for 2 min, and incubated with 50 μL of
ME1 or W6/32 for 20 min at 4 °C (10 and 20 μg/mL respectively). The
cells were washed twice with 200 μL of PBS, incubated with FITC-
conjugated anti-mouse IgG secondary antibody (eBioscience, San Di-
ego, CA) at 1 μg/mL for 20 min, at 4 °C, and washed twice with PBS. The
detection was made using a FACSCalibur instrument (BD Bioscience,
San José, CA) with CellQuest Pro version. All data were analyzed using
the FlowJo software, version 7.5 (Tree Star, Inc, Ashland, OR).

Isolation of HLA-A*B*B*27:05-bound Peptidomes—About 1 × 10⁶
cells were lysed at 4 °C in 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1%
lglucosylglycoprotein (Sigma-Aldrich) and a mixture of protease inhibitors
(Roche, Mannheim, Germany). After centrifugation, the supernatant
was passed through a column containing the ME1 mAb bound to
CnBr-activated Seaphorose 4B (GE Healthcare, Buckinghamshire, UK)
and washed with 20 column volumes each of 20 mM Tris-HCl, pH 8.0
containing: 1) 150 mM NaCl, 2) 400 mM NaCl, 3) 150 mM NaCl, and 4) 40
column volumes of buffer without NaCl. Peptides were eluted with 1%
TFA (Sigma-Aldrich) at room temperature, filtered through Vivas-

Molecular & Cellular Proteomics 17.7 1309
pin 2, cutoff 5000 Da (Sartorius Stedim Biotech, Gottingen, Germany), concentrated in a SpeedVac and subjected to reversed phase purification using OMIX tips (Varian Inc, Palo Alto, CA) by elution with 50% acetonitrile, 0.1% TFA in water. The eluted peptides were dried and stored at −20 °C. For each LCL, three preparations were independently obtained from the same cell amounts.

**Mass Spectrometry**—The recovered peptides were analyzed in a Q-Exactive-Plus mass spectrometer fitted with Ultimate 3000 RSLC nanocapillary UHPLC (Thermo Fisher Scientific, Waltham, MA). The peptides were resolved on a capillary column (75 μm ID and ~20 cm long) pressure packed as in (41) with C18 reversed-phase 3.5 μm beads (RepriSil-C18-Aqua, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany), using a 7–28% acetonitrile gradient with 0.1% formic acid during 180 min followed by 28–95% during 15 min. The flow rate was 0.15 μL/min. The dynamic exclusion was set to 20 s and the automatic gain control value for the full MS was set to 3 × 10^6. The selectivity was determined from the survey scan of mass-to-charge ratio (m/z) 300–1800 AMU at resolution 70,000. Data was acquired using a data-dependent “top-10” method, fragmenting the peptides by higher-energy collisional dissociation. MS/MS spectra were acquired starting at m/z 200 with a resolution of 17,500. The target value of the MS/MS was set to 1 × 10^6 and the isolation window to 1.8 m/z. The maximum injection time was set to 100 ms and normalized collision energy to 25 eV. No fragmentation was performed for peptides with unassigned precursor ion charge states or charge states of four and above. The peptide match option was set to Preferred. Fragmented masses were dynamically excluded from further selection for fragmentation for 20 s.

**Experimental Design and Statistical Rationale**—HLA-B*27-bound peptides were isolated from three independent preparations of each of the four LCL used in this study, to provide for biological replicates. About 1 × 10^5 cells were used for each preparation. The peptides were fragmented by mass spectrometry, as detailed above, and their sequences were assigned, from the MS/MS spectra, using the MaxQuant software (version 1.5.0.25) (42) with the Andromeda search engine (43) and the human UniProt/Swiss-Prot database (release 2015_07, 20197 entries) under the following parameters: precursor ion mass and fragment mass tolerance 20 ppm, false discovery rate (FDR) 0.05 for peptide-spectrum matching. N-terminal acetylation, Gln-to-pyroglutamic cyclation and Met oxidation were included as variable modifications. No fixed modifications were included. Identities derived from the reverse database and known contaminants were excluded. Neither the specificity of proteases used to generate peptides, nor the missed/non-specific cleavages permitted applied to our analysis, as it concerns peptides endogenously generated in live cells. Peptides in the length range of 8 to 14 amino acid residues, corresponding to most MHC-I ligands, with Arg or Gln at peptide position (P) 2, which is the major anchor motif of HLA-B*27, were assigned as B*27:05 ligands. This selection removes most of the contaminant peptides unrelated to MHC-I and to non-B*27 MHC-I ligands.

To assess the effect of the ERAP1 background in each LCL on the B*27:05 peptidome we carried out quantitative comparisons of the shared ligands between cell line pairs. Six such comparisons were carried out, each one addressing the effects of ERAP1 polymorphisms (Table I). Prior to these comparisons, the ion peak intensity of each peptide in each cell line was normalized to the total intensity of the ion peaks corresponding to all the identified peptides in that cell line after filtering for length and P2 residues as described above, so that the intensity of irrelevant signals was not considered. This normalization also corrects for differences in peptide yields arising, for instance, from distinct HLA-B*27 expression among cell lines. The normalization was done in each individual experiment and the normalized ion peak intensities assigned to the peptides from each cell line were the mean values from the three experiments. The ratio between the normalized intensities of a given peptide in the two cell lines (IR) was taken as an indication of the relative amounts of that peptide.

The shared peptides between any given cell line pair were classified as follows: Those that were more abundant in one cell line, relative to the other (IR > 1.0), were subdivided in those with IR > 1.0 to 1.5 (hereafter abbreviated as IR > 1.0–1.5) and those with IR > 1.5. The former subset included the peptides with similar or slightly increased levels in one cell line relative to the other. The IR > 1.5 subset included those peptides showing higher expression differences in each cell line compared with the other. This classification is based on our previous studies showing that ERAP1/ERAP2-dependent differences in MHC-I peptidomes are best revealed among peptides in the IR > 1.5 subset and are usually attenuated or absent altogether in the IR > 1.0–1.5 group. This is expected from the fact that quantitative effects of ERAP1 polymorphism on MHC-I ligands should be mainly observed among peptides showing larger differences in relative amounts between the cell lines compared. The relationship of this classification to the statistical significance of the differences in peptide amounts was established by means of Volcano plots for each pairwise comparison. In these analyses the Student’s t test was used to assess the statistical significance of the expression differences of individual peptides in the two cell lines compared.

**Recombinant ERAP1 Proteins and Hydrolytic Assay**—The purification of recombinant ERAP1 proteins and the hydrolysis assay with the fluorogenic substrate Leu-7-amido-4-methyl-coumarine (L-AMC) were carried out exactly as previously described (23).

**Classification of Amino Acid Residues According to ERAP1 Susceptibility**—Amino acid residues were classified according to their susceptibility to ERAP1 (12), as ERAP1-susceptible (A, C, L, M, Y), intermediate (F, G, H, I, N, Q, S, T), or resistant (D, E, K, P, R, V, W), as previously described (25).

**Binding Affinity**—Theoretical binding affinities of B*27:05 ligands were calculated using the NetMHCcons 1.1 Server (http://www.cbs.dtu.dk/services/NetMHCcons/), which integrates three different algorithms, as described elsewhere (44).

**Statistical Analyses**—Differences in peptide length and residue frequencies were assessed by the χ^2 test with Bonferroni correction, when applicable. Differences in binding affinity were analyzed by the Mann-Whitney U test. The Student’s t test was used to assess the statistical significance of the expression differences of individual peptides among cell lines. p < 0.05 was considered as statistically significant in all cases.

**RESULTS**

**ERAP1, ERAP2, and HLA-B*27 Peptidome in HLA-B*27:05 Positive Cell Lines**—Although the expression of ERAP1 and ERAP2 in the four cell lines used in this study were separately assessed in previous reports (26, 35), their relative protein levels were jointly determined by Western blotting in the context of the present study (Fig. 1A–1B). For ERAP1 they were the following: LCL 6370 (100), LG2 (75 ± 7), P50 (80 ± 10), C1R05 (54 ± 5). ERAP2 expression was similar in the four cell lines, as previously reported.

Total MHC-I expression was highest in the C1R05 transfected, followed by P50, and was lowest and similar for LCL 6370 and LG2 (Fig. 1C). Accordingly, HLA-B*27 expression was highest for C1R05, followed by LG2 and P50. LG2 is homozygous for HLA-B*27 and its expression was roughly double compared with the heterozygous LCL 6370. Although P50 is also homozygous for HLA-B*27, its relatively high
Fig. 1. ERAP1, ERAP2 and MHC-I expression in LCL. A, Expression of ERAP1 proteins in the indicated cell lines. A representative experiment (top) and the mean ± standard deviation of 3 independent analyses (bottom) are shown. The results are expressed as the amounts of ERAP1 relative to the cell line with the highest expression of the enzyme. B, ERAP2 protein expression in the same cell lines; conventions are as in panel A, except that a single experiment (top) and its quantization (bottom) is shown, because the similar expression of ERAP2 in these four cell lines was previously reported (26, 35). C, Flow cytometry analysis of the surface expression of MHC-I antigens in LCL 6370 ( . . . ), C1R05 ( _____ ), LG2 ( . . . . ), and P50 (—), as assessed with the W6/32 mAb. A representative measurement (top) and the mean ± standard deviation of triplicate samples (bottom) is shown, with mean fluorescent values made relative to the cell line with the highest MHC-I expression. D, Flow cytometry analysis of the surface expression of HLA-B*27 as assessed with the ME1 mAb. Conventions are as in panel C. Note that P50 expresses HLA-B*14, which shows some reactivity with ME1.
staining with ME1 is explained both by the higher overall expression of MHC-I molecules (Fig. 1C) and by the moderate cross-reaction of ME1 with HLA-B*14 (38, 39), which is also expressed in this cell line.

Identification of HLA-B*27:05 Ligands Presented in Various ERAP1 Contexts—The B*27:05 peptidomes from LCL 6370, LG2, C1R05 and P50, isolated from three independent preparations for each cell line, were analyzed by MS. A total of 9162 peptides with 8 to 14 amino acid residues and Arg2 or Gin2 were assigned as B*27:05 ligands in one or more of the four LCL, of which 6894 (LCL 6370), 6094 (LG2), 7205 (C1R05), and 6620 (P50) were detected in the individual cell lines (supplemental Table S1). The molecular weight and length distributions of the identified B*27:05 ligands were very similar among cell lines, although a small increase of 9-mers, and a corresponding decrease of longer peptides, was observed in LCL 6370/LG2 (Hap2/Hap3)—This comparison allowed us to assess the effect of the Q730E change in ERAP1 (Table I). The peptides with IR>1.0 showed a significantly higher percentage of peptides ≤9-mers (8-mers were ≤1% in all cases) in LG2 (E730), and a corresponding decrease of longer peptides, relative to LCL 6370 (Q730) (Fig. 2A). This difference was larger between the IR>1.5 subsets, and virtually nonexistent between the IR>1.0–1.5 subsets of both cell lines (supplemental Fig. S3A). No differences were observed in the P(-1) frequencies, indicating that the Q730E change has little influence on epitope generation as a function of the susceptibility of P(-1) residues to ERAP1 (Fig. 2B, supplemental Fig. S3B). In contrast, a decrease of P1 residues with high susceptibility to this enzyme was found in the IR>1.5, but not in the IR>1.0–1.5 subset of LG2 (supplemental Fig. S3C). The same effect was observed among the whole set of predominant peptides (IR>1.0) from this cell line, which included both subsets (Fig 2C). In this and all subsequent comparisons the differences observed between the IR>1.0 peptide sets reflect mainly those in the IR>1.5 subsets but are often somewhat attenuated because of the lack of differences between the IR>1.0–1.5 subsets. Thus, E730 in LG2 confers higher trimming activity, which is reflected both in higher amounts of shorter peptides and increased destruction of B*27:05 ligands with

### Table I

**ERAP1 and ERAP2 phenotypes of the cell lines used in this study**

| Comp. | ERAP1 | 12 | 56 | 127 | 276 | 346 | 349 | 528 | 575 | 725 | 730 | ERAP2 | Ref. |
|-------|-------|---|----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-----|
| 6370  | Hap2  | T | E  | R  | I  | G  | M  | K  | D  | R  | Q  | +     | (34) |
| LG2   | Hap3  | T | E  | R  | I  | G  | M  | K  | D  | R  | E  | +     | (26) |
| LG2   | Hap3  | T | E  | R  | I  | G  | M  | K  | D  | R  | Q  | +     | (25) |
| C1R05 | Hap8  | T | E  | P  | M  | G  | M  | R  | D  | R  | E  | +     | (26) |
| 6370  | Hap2  | T | E  | R  | I  | G  | M  | K  | D  | R  | Q  | +     | (34) |
| C1R05 | Hap8  | T | E  | P  | M  | G  | M  | R  | D  | R  | E  | +     | (26) |
| P50   | Hap10 | T | E  | P  | I  | G  | V  | R  | N  | Q  | E  | +     | (26) |
| LG2   | Hap3  | T | E  | R  | I  | G  | M  | K  | D  | R  | Q  | +     | (26) |
| P50   | Hap10 | T | E  | P  | I  | G  | V  | R  | N  | Q  | E  | +     | (26) |

* Haplotypes and amino acid residues associated with AS risk are in boldface and underlined.
ERAP1-susceptible P1 residues. These alterations only marginally affected the global affinity of the B*27:05 peptidome (Fig. 2D, supplemental Fig. S3).

LG2/C1R05 (Hap3/Hap8)—This comparison allowed us to assess the effect of the R127P/I276M/K528R changes in ERAP1, in the E730 context (Table I). Previous in vitro analyses failed to show any effect of the R127P change on substrate trimming (27, 34) and there is also no evidence that the non-AS-associated I276M mutation has any functional effect. Thus, the major influence of these mismatches is probably conferred by the K528R change.

A significantly higher percentage of peptides ≤9-mers, to the expense of longer peptides, was observed in LG2 (K528), relative to C1R05 (R528) cells, both in the IR>1.0 and IR>1.5 subsets, but not in the IR>1.0–1.5 subsets, reflecting increased trimming by the K528 variant (Fig. 3A and supplemental Fig. S4A). This effect was comparable to that conferred by the Q730E change. However, the risk alleles in both positions (K528 and Q730) showed opposite effects.

The higher activity of the K528 variant in LG2 was also reflected in a lower frequency of P(-1) and P1 residues with high sensitivity to ERAP1 trimming and a corresponding increase of ERAP1-resistant residues (Fig 3B–3C and supplemental Fig. S4B–S4C). These effects were clearly higher than those observed across the Q730E change (Fig. 2B–2C), indicating that the K528R and Q730E alter the generation/destruction balance of B*27:05 ligands in very distinct ways. The high activity conferred by K528 resulted in a significantly higher affinity of the peptides in the IR>1.0 and IR>1.5 subsets from LG2, relative to C1R05 (Fig. 3D and supplemental Fig. S4D).

LCL 6370/C1R05 (Hap2/Hap8)—This comparison allowed us to assess the added effect of the Q730E change on the R127P/I276M/K528R mismatch (Table I). As expected, a

### TABLE II

Summary of statistically significant differences in pairwise comparisons among LCL

| Comparison | IR>1 | Length | P(-1) residues with higher ERAP1 susceptibility | P1 residues with higher ERAP1 susceptibility | Increased affinity |
|------------|------|--------|-----------------------------------------------|-----------------------------------------------|-------------------|
|            |      | Total  | Total 9-Mers | Total 10-Mers | 9-Mers | 10-Mers | Total 9-Mers | 10-Mers |
| 6370/LG2   | 1.4E-33 | NS    | 2.2E-03 | 3.2E-05 | 2.8E-04 | 1.6E-02 | <1.0E-04 | 1.9E-02 |
| LG2/C1R05  | 1.6E-25 | 7.1E-03 | 3.2E-12 | 1.5E-16 | 2.5E-05 | <1.0E-04 | 1.9E-02 |
| 6370/P50   | 1.1E-08 | 0.03   | 1.3E-19 | 3.9E-12 | 9.3E-13 | <1.0E-04 | 1.9E-02 |
| LG2/P50    | 2.5E-31 | 7.1E-08 | 5.3E-18 | 4.7E-13 | 1.7E-13 | <1.0E-04 | 1.9E-02 |
| C1R05/P50  | 7.1E-09 | 3.5E-07 | 1.4E-10 | 4.2E-07 | 3.7E-03 | <1.0E-04 | 1.9E-02 |

a The data correspond to the IR>1.0 subsets of B*27:05 ligands in all comparisons. Statistical values in boldface or underlined are increased in the equally coded cell lines.

b Values correspond to increased percentage of 9-mers.

c For the purpose of this table, to simplify the representation, residues were subdivided in only two groups, with the residues of intermediate susceptibility to ERAP1 (F, G, H, I, N, Q, S, T) being joined to those of either low (D, E, K, P, R, V, W) or high susceptibility (A, C, L, M, Y) depending on the tendencies observed in Figs. 2–8. The statistical differences refer to the joint frequency of residues in each category.

---

**Fig. 2.** Comparison of the shared peptides between LCL LG2 and 6370: IR>1.0 subsets. A total of 2444 (LG2: white bars) and 2869 (6370: black bars) peptides were included in the IR>1.0 subset from each cell line. A, Peptide length distribution, B, Percentage of P(-1) residues with low, intermediate and high susceptibility to ERAP1, C, Percentage of P1 residues with low, intermediate and high susceptibility to ERAP1, D, Theoretical affinity of the peptides for B*27:05, as estimated by their IC50 values. When the differences reached statistical significance, this was indicated by their p values.
higher percentage of peptides ≤9-mers, to the expense of longer peptides, was observed in LCL 6370 (K528/Q730) relative to C1R05 (R528/E730) in both the IR>1.0 and IR>1.5 subsets, consistent with the presence of K528 in the ERAP1 variant of the former LCL (Fig. 4A and supplemental Fig. S5A). However, these differences were smaller than those in LG2/C1R05 (KE/RE), strongly suggesting that Q730 in LCL 6370 diminish the length effects of K528.

The effects on P(-1) residues were somewhat lower, and those on P1 higher (Fig. 4B–4C and supplemental Fig. S5B–S5C), than in LG2/C1R05 (Fig. 3B and supplemental Fig. S4B). This is consistent with a length-dependent effect of the Q730E change on trimming.

The global affinity of the predominant peptides was higher in LCL 6370 than in C1R05 (Fig. 4D and supplemental Fig. S5D), to an extent like that in LG2/C1R05. This is consistent with the small effects of Q730E on the affinity of the B*27:05 peptidome (Fig. 2D).

The increased expression of ERAP1 in LG2 and 6370 cells, compared with C1R05, is frequently observed among ERAP1 variants with K528, relative to those with R528 (20, 45), which enhances the effect of this mutation.
C1R05/P50 (Hap8/Hap10)—This comparison intended to address the joint effect of the M276I/M349V/D57N/R725Q changes in ERAP1, upon concordance at residues R528 and E730 (Table I). Peptide length distribution and P(-1) usage were very similar among the predominant B*27:05 ligands from both cell lines (Fig. 5A–5B and supplemental Fig. S6A–S6B). In contrast, an increase of ERAP1-resistant P1 residues, with a concomitant decrease of those with intermediate susceptibility, as well as increased affinity, was observed in P50, relative to C1R05, in the IR>1.0 and IR>1.5 subsets, but not in the IR>1.0–1.5 subsets (Fig. 5C–5D and supplemental Fig. S6C–S6D).

To address the possibility that these effects were because of the 1.5 to 2-fold higher ERAP1 expression in P50 cells, relative to C1R05, recombinant Hap8 and Hap10 variants of ERAP1 were tested for their hydrolytic activity toward L-AMC at the same or at a double (×2) E:S ratio. When the differences in panels A–D reached statistical significance, this was indicated by their p values.
LCL 6370/P50 (Hap2/Hap10)—This comparison addressed the effect of a major AS-associated ERAP1 haplotype, Hap2, relative to the AS-protective haplotype, Hap10 (Table I). It allowed us to assess the effect of the M349V/D575N/R725Q changes when they occur along R127P/K528R/Q730E, whose effects were examined in the 6370/C1R05 comparison. A comparative analysis of B*27:05 ligands from LCL 6370 and P50, involving much less peptides, was previously reported (35).

The higher activity of ERAP1 in LCL 6370, relative to P50, was obvious from its effects, observed in both the IR>1.0 and IR>1.0–1.5 subsets, on increasing the percentage of peptides ≤9-mers (Fig. 6A and supplemental Fig. S7A), and in the lower percentages of B*27:05 ligands with ERAP1-sensitive P(-1) or P1 residues (Fig. 6B–6C and supplemental Fig. S7B–S7C), resulting in a B*27:05 peptidome of higher affinity (Fig. 6D and supplemental Fig. S7D).

The differences in length and P(-1) usage were larger than those observed in 6370/C1R05 (Fig. 4 and supplemental Fig. S5), indicating that the additional M349V/D575N/R725Q changes in P50 further diminish ERAP1 activity.

LG2/P50 (Hap3/Hap10)—Like the previous one, this comparison addressed the effect of another major AS-associated ERAP1 haplotype, Hap3, relative to Hap10 (Table I). It allowed us to assess the effect of the M349V/D575N/R725Q changes when they occur along R127P/K528R, whose effects were examined in the LG2/C1R05 comparison (Fig. 3 and supplemental Fig. S4). The major difference between the 6370/P50 and LG2/P50 comparisons is the concordance of E730 in the latter cell line pair.

The differences between the B*27:05 ligands from LG2 and P50 in the IR>1.0 or IR>1.5 subsets were larger in peptide length and in the trimming of P(-1) residues (Fig. 7A–7B and supplemental Fig. S8A–S8B) than those in LG2/C1R05 (Figs. 3 and supplemental Fig. S4). Thus, again, the M349V/D575N/R725Q changes add to the dominant effect of K528R in decreasing the enzymatic activity of ERAP1. Yet, the alterations in P1 frequencies and affinity were similar or slightly smaller in LG2/P50 (Fig. 7C–7D and supplemental Fig. S8C–S8D) compared with LG2/C1R05.

Residue 730 Modulates the Effects of ERAP1 on the HLA-B*27 Peptidome as a Function of Peptide Length—A previous study using poly-Gly peptide analogs and in vitro digestions showed that the Q730E polymorphism affects substrate length selection by increasing ERAP1 preference for shorter substrates (47). To establish the significance of this effect in live cells we examined the differences in P1 residue frequencies and affinity between the B*27:05 ligands in the IR>1.0 subsets from each cell line, separately considering the 9-mers and the peptides ≤10-mers in each pairwise comparison (Fig. 8). In LCL 6370/LG2 (Fig. 8A), the percentage of 9-mers with ERAP1-resistant residues was higher in LG2 (E730), because of increased destruction of 9-mers with ERAP1-susceptible residues, indicating higher activity of the E730 variant for these peptides. The opposite situation was found for peptides ≥10-mers, where the frequency of ERAP1-resistant residues was higher in LCL 6370 (Q730). This result confirms that the Q730E change in ERAP1 leads to higher activity toward 9-mers and lower trimming of longer peptides, demonstrating the significant influence of this polymorphism on the length of HLA-B*27 ligands in live cells.

In LG2/C1R05 (Fig. 8B) and LG2/P50 (Fig. 8C), all concordant in E730, the frequency of ERAP1-resistant P1 residues was much higher among 9-mers than among longer peptides. This can be explained by the concurrence of two effects adding to each other in both comparisons. The first one is that...
the lower activity of ERAP1 because of the K528R and other polymorphisms in C1R05 and P50 becomes more critical for 9-mers, because they are close to the lowest substrate length suitable for this enzyme. The second effect is that E730 in ERAP1 confers higher trimming efficiency for 9-mers, relative to longer peptides.

The influence of the Q730E polymorphism on the effects of K528R became apparent in the LCL 6370/C1R05 and 6370/P50 comparisons (Fig. 8D–8E). In both cases the frequencies of ERAP1-resistant P1 residues in 9-mers and peptides >10-mers were similarly increased in LCL 6370 (K528/Q730), relative to C1R05 or P50 (both with R528/E730). This can be explained by the fact that K528 confers higher trimming than R528, regardless of peptide size. However, Q730 confers lower trimming than E730 for 9-mers and higher trimming of longer ones, so that the activity differences between K528/Q730 and R528/E730 are larger for peptides >10-mers, resulting in similar effects on P1 residue frequencies regardless of peptide length.

These length-dependent effects of Q730E resulted in a distinct influence on affinity when 9-mers or peptides >10-mers were separately considered. The effect was most dramatic upon concordance at other positions, as in the 6370/LG2 comparison (supplemental Fig. S9): the affinity of 9-mers was higher for LG2 (E730) and that of peptides >10-mers was higher for LCL 6370 (Q730).

Influence of ERAP1 Polymorphism on the Sequence of B*27:05 Ligands Downstream the N Terminus—The residue frequencies of B*27:05 9-mers in the IR>1.0 subset from each cell line were analyzed in all pairwise comparisons. Statistically significant differences were found at most peptide positions with a pattern that was different in each cell line pair (Table III). These results indicate that ERAP1 polymorphism shapes the HLA-B*27 peptidome not only by differential trimming of P(-1) and P1 residues, but also by favoring or disfavoring peptides with distinct internal sequences.

Peptides Selectively Found in Individual Cell Lines—Peptides selectively found in only one cell line in pairwise comparisons ranged about 13% to 30% percent of the total peptides in that cell line (supplemental Table S2). These peptides showed differences both in length and frequency of P1 residues with distinct susceptibility to ERAP1 that were generally very similar as those observed when the shared peptides predominant in the same cells lines (IR>1.0) were compared (supplemental Fig. S10).

It is important to note that in our MS analyses failure to detect a peptide in a given pool does not mean that the peptide is absent. Thus, these subsets encompass: (1) truly cell-specific ligands, including peptides specifically generated in one particular ERAP1 context, (2) occasional contaminating ligands of non-B*27 MHC-I molecules not shared between the cell lines compared, (3) peptides that are expressed in very low amounts or were fortuitously undetected in one of the cell lines. Except for C1R05, from which many more peptides were identified, the percentage of peptides found only in one of the four cell lines compared was small: 2.3% (LG2), and 4.7% (LCL 6370 and P50). These numbers might reflect somewhat better the maximal percentages of epitopes specifically generated in a given ERAP1 context. Yet, for the reasons explained above, the actual number of ERAP1 haplotype-specific peptides is probably much lower.

DISCUSSION

This study provides a comprehensive characterization of the effects of ERAP1 polymorphism on the B*27:05 peptidome in live cells, effects which are presumably at the basis of the epistatic association of both molecules with AS. The...
Fig. 8. Length-dependent effects of ERAP1 polymorphism on P1 residue usage. Percentage of P1 residues of 9-mers (left panels) and ≥10-mers (right panels) from the IR>1.0 subsets with low, intermediate and high susceptibility to ERAP1. A, A total of 1431 (from LCL 6370: Black bars) and 1616 (from LG2: White bars) 9-mers, and 1431 and 813 peptides ≥10-mers, respectively, were compared. B, A total of 1443 (LG2: Black bars) and 1417 (C1R05: White bars) 9-mers, and 761 and 1380 peptides ≥10-mers, respectively, were included. C, A total of 1720 (LG2: Black bars) and 1117 (P50: White bars) 9-mers, and 786 and 1413 peptides ≥10-mers, respectively, were included. D, A total of 1432 (LCL 6370: Black bars) and 1543 (C1R05: White bars) 9-mers, and 1024 and 1522 peptides ≥10-mers, respectively, were included. E, A total of 1689 (LCL 6370: Black bars) and 1251 (P50: White bars) 9-mers, and 1079 and 1504 peptides ≥10-mers, respectively, were included. When the differences reached statistical significance, this was indicated by their p values.
main features defining the association of ERAP1 with this disease can be summarized as follows: (1) one or more of the Hap1-Hap3 haplotypes predispose to AS whereas Hap10 is protective (14), (2) the K528R polymorphism is a major factor influencing the association, with K528 being the risk variant (16), (3) a secondary factor influencing AS risk is the presence of D575/R725 (16), but this may actually be because of a linked polymorphism influencing protein levels (19), (4) on the basis of fine-mapping studies, it seems plausible that the Q730E polymorphism might not be directly associated with AS (21). Thus, it is important to address the correspondence between the genetic contribution of ERAP1 polymorphisms to AS and their biochemical effects because such correspondence will highlight the changes in the peptidome that may be more relevant to the pathological role of HLA-B*27.

Previous studies both in vitro (16, 27–29) and on live cells (26) have established a major effect of the K528R polymorphism on ERAP1 activity and on the HLA-B*27 peptidome, with the protective R528 variant leading to decreased activity. Although the D575N/R725Q changes lead to lower activity in vitro (24), a previous study in live cells failed to detect any significant effect (26). Concerning Q730E, in vitro studies with poly-Gly peptides revealed that the Q730 variant showed higher activity than E730 for 10-mers and longer substrates, and lower activity for 9-mers and shorter peptides. This polymorphism influenced the surface expression of free HLA-B*27 heavy chains on monocytes in one study (48), but its effects on MHC-I-bound peptidomes in live cells has not been previously explored.

We addressed two main issues: (1) to distinguish and rank the effects of each of the Q730E, K528R, and D575N/R725Q polymorphisms on the B*27:05 peptidome, and (2) to characterize their joint effects in the risk (Hap2, Hap3) and protective (Hap10) haplotypes.

Our study was mostly focused on the quantitative differences among shared HLA-B*27 ligands expressed in distinct ERAP1 contexts for two reasons. The first one is the logical assumption that the same rules determining quantitative differences in the amounts of certain ligands as a function of the ERAP1 polymorphism should apply, in the extreme, to epitopes that are presented in one context but not in other. The second reason is that in our analyses, failure to detect a peptide in a given pool does not necessarily mean that the peptide is absent. Therefore, we cannot determine how many peptides are specifically generated or destroyed in a given context. Our study was not designed for that purpose, but to address the effects of ERAP1 variants on the amount of peptides with given features, resulting from changes in their generation/destruction balance.

The ERAP1 polymorphisms analyzed influenced the B*27:05 peptidome at five levels: peptide length, frequency of P(-1), P1, and internal residues, and peptide affinity. In general, the effects on P(-1) residues were smaller than on P1 suggesting that, for N-terminal residues with equal susceptibility to trimming, ERAP1 polymorphism has more influence on modulating epitope destruction than epitope generation. Nonamers are generally less efficiently trimmed than longer peptides, because they are close to the lowest substrate length handled by this enzyme (13). Thus, activity differences among ERAP1 variants are likely to affect more drastically the relative trimming of distinct N-terminal residues of natural B*27:05 ligands, particularly 9-mers, than those of their precursors. The altered frequencies of internal residues may reflect a direct influence of ERAP1 polymorphism on substrate handling because binding and trimming by ERAP1s influenced by the internal sequence of the substrate (49), be a compensatory effect for the changes in binding affinity to B*27:05 induced by P1 alterations, or both.

Key to understanding the effects described in this study was that the Q730E polymorphism alone induced distinct alterations depending on peptide length, with the E730 variant leading to a substantially increased abundance of 9-mers. This observation is fully consistent with the activity pattern of the Q730 and E730 variants defined in vitro (47) and, for the first time to our knowledge, demonstrates that this pattern has general significance and large effects in a natural peptidome processed in live cells. This mutation had moderate effects on P1 residue usage and affinity on the whole peptidome, but this was because of the fact that such effects were opposite for 9-mers and peptides ≥10-mers, again reflecting the distinct length-dependent activity of these variants.

The effects of K528R, although comparable in magnitude to those of E730Q on peptide length, were substantially larger on all other features examined, reflecting the higher activity of the
ERAP1 Polymorphism and the HLA-B*27 Peptidome

AS-associated K528 variant. It also revealed similar trends for peptides with different lengths, again in agreement with studies using poly-Gly analogs (47). In our previous study (26), carried out at lower resolution and with much fewer peptides identified, the effects of K528R on P1 residue usage were detected, but those on P(-1) and peptide length went unnoticed.

The molecular bases for the distinct effects of the Q730E and K528R changes have been analyzed in detail by Stratikos and colleagues (47, 50). Residue 528 is in an interdomain region of ERAP1 and has a major effect on the dynamics of the conformational transitions driving the acquisition of enzymatic activity. In contrast, residue 730 is in the substrate-binding site, has less influence on the conformational dynamics of the molecule and a more prominent effect on substrate binding.

Concerning D575N/R725Q, its effects could be better assessed by comparing the results in LG2/P50, where these changes co-occurred with K528R, and LG2/C1R05, with the K528R mismatch and concordance at residues 575 and 725 (Table I). These comparisons demonstrated that D575N/R725Q negatively influenced the enzymatic activity of ERAP1, adding to the substantially higher effect of K528R.

The length-dependent effects of the Q730E polymorphism on the B*27:05 peptidome imply that the influence of all other changes analyzed in the pairwise comparisons must take into account the concordance or discordance at residue 730. ERAP1 activity is E>Q730 for peptides ≤9-mers and E<Q730 for longer peptides, but K>R528 independently of peptide length. Thus, the following activity ranking of ERAP1 variants can be established: KE>KQ>RE>RQ for peptides ≤9-mers, and KE>KE>RQ>RE for longer peptides. In LG2/C1R05 and LG2/P50 (KE versus RE in both cases), the effect of E730 on favoring trimming of 9-mers more than longer peptides implies that the higher activity of K528 in LG2 will be further increased by E730 for 9-mers more than for peptides ≥10-mers, as was actually observed in the much higher effects on P1 residue usage for 9-mers in both comparisons. Concordance at residue 730 in 6370/C1R and 6370/P50 (KQ versus RE in both) implies that Q730E will increase the differences in enzymatic activity and trimming for peptides ≥10-mers (KQ>RQ>RE) but will attenuate this effect on 9-mers and shorter peptides (KQ>RE). As a result, the differences in P1 residue usage were similar for 9-mers and longer peptides in both comparisons. This contrasting effect was also reflected on peptide length: the increase of 9-mers was substantially higher in LG2/P50 and LG2/C1R than in 6370/P50 and 6370/C1R05, respectively (Table II).

The combined influence of K528R and Q730E on the B*27:05 peptidome is consistent with enzymological studies suggesting that the effects of both mutations are independent and additive (47). Our results reflect the full dimension of these combined effects on a highly complex MHC-I-bound peptidome expressed on live cells.

There is a general concordance between the biochemical and genetic data concerning the role of functional ERAP1 polymorphism. This applies to the major role of K528R on the genetic risk of ERAP1 in AS, on enzymatic activity and on the B*27:05 peptidome. The secondary role of D575N/R725Q both on AS risk and on the B*27:05 peptidome adds to this concordance, although in this case the genetic influence of this polymorphism, as tagged by the rs10050860 SNP (D575N), may be determined by another polymorphism in tight linkage disequilibrium, in particular the splice-altering SNP rs7063 (19).

The relationship between the role of Q730E in AS and the biochemical effects of this polymorphism is more difficult to assess. Its substantial influence on the B*27:05 peptidome, suggests that the Q730E change may directly influence AS susceptibility. Yet, unlike other polymorphisms in which the protective alleles are “loss-of function” variants leading to decreased enzymatic activity, the protective E730 allotype shows higher activity than the risk counterpart Q730 for 9-mers, which account for most of the HLA-B*27 peptidome. Indeed, the patterns of peptide length distribution and P1 residue usage among 9-mers were very similar for the risk variant K528 and the protective E730. This functional paradox might be resolved if the AS protective effect of Q730E suggested by earlier studies (15, 20) would be because of linkage disequilibrium with the neighbor AS-associated region defined by more recent fine-mapping (21), which does not include rs27044 (Q730E). Studies on haplotype associations, reviewed in (14), established the protective role of Hap10 (with E730) and suggested that Hap1-Hap3 predispose to AS. These haplotypes are discordant at residue 730: Q730 in Hap1 and Hap2, E730 in Hap3. To our knowledge, no genetic studies involving the association of whole ERAP1 haplotypes with AS have specifically addressed whether Hap2 and Hap3, discordant only at Q730E, differ in the strength of their association with AS.

In conclusion, the epistatic association of ERAP1 with AS can be rationalized based on a complex and significant influence of the enzymatic polymorphism on the HLA-B*27 peptidome. This influence affects multiple peptide features, altering the generation/destruction balance of a large fraction of the peptidome and its affinity. Distinct polymorphic residues act differently on each of these features and their contribution seems to be, to a large extent, additive. Thus, the differential effects of AS-predisposing and AS-protective haplotypes on the B*27:05 peptidome is the combined result of the distinct influence, both quantitative and qualitative, of the polymorphisms involved. The magnitude of these changes can profoundly affect antigen presentation and, presumably, other pathogenetic features of HLA-B*27, such as folding and cell surface stability, providing a peptide-mediated basis for the joint association of ERAP1 and HLA-B*27 with AS.

In at least two other MHC-I associated inflammatory disorders, psoriasis and Behc¸e’s disease, ERAP1 is associated with disease in epistasis with the risk MHC-I alleles, C’06:02
and B*51:01, respectively (17, 18). Like in AS, the risk ERAP1 haplotypes in psoriasis seem to be Hap1–3, with Hap2 being an important risk factor at least among East Asians, and Hap10 being protective (14). The features of the C*06:02 peptidome were recently determined (51). Similarly to HLA-B*27, Arg2 was a major motif, whereas aromatic residues were predominant at P1. To our knowledge the influence of ERAP1 on the C*06:02 peptidome has not yet been experimentally addressed. Yet, compared with HLA-B*27, the distinct susceptibility of the preferred P1 residues to ERAP1 may imply large differences in the over-trimming and destruction of C*06:02 ligands, depending on these residues and the enzymatic activity of ERAP1 variants. In contrast to AS and psoriasis, the low activity Hap10 variant of ERAP1 is the risk factor for Behçet’s disease (52). The peptidome of B*51, an allotype strongly associated with this disease, consists mainly of two subpeptidomes, with Pro2 and Ala2 respectively, which differ in their susceptibility to ERAP1 and in their binding affinity (48). The main effect of Hap10 on this peptidome is to upset the relative amounts of both subpeptidomes, resulting in a peptidome of globally lower affinity, which is predicted to alter NK recognition of HLA-B*51 (53). Thus, although detailed studies, such as those reported here for HLA-B*27, have not yet been performed on other disease-associated MHC-I allotypes, ERAP1 polymorphism can significantly alter the nature of their peptidomes, changing in this way their immunological features and providing a sound basis for the epistatic association of ERAP1 and MHC-I with distinct inflammatory diseases.

DATA AVAILABILITY

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (http://www.ebi.ac.uk/pride) with the dataset identifier PXD008500.

This work is supported by grants SAF2014/51931-R (Plan Nacional de I+D+i) to JALC, Israel Science Foundation grant 1435/16 to AA, and an institutional grant of the Fundación Ramón Areces to the Centro de Biología Molecular Severo Ochoa.

[5] This article contains supplemental material.

To whom correspondence should be addressed: Centro de Biología Molecular Severo Ochoa, c/Nicolás Cabrera, N. 1, Universidad Autónoma, 28049 Madrid, Spain. Tel.: 34-91 196 4554; E-mail: aldecastro@cbm.csic.es.

Author contributions: A.S.-B. and J.A.L.d.C. designed research; A.S.-B., A.M.-E., and J.A.L.d.C. analyzed data; A.S.-B. and A.M.-E., E.B., and A.A. performed research; A.S.-B., A.M.-E., E.B., and A.A. contributed new reagents/analytic tools.

REFERENCES

1. Saric, T., Chang, S. C., Hattori, A., York, I. A., Markant, S., Rock, K. L., Tsujimoto, M., and Goldberg, A. L. (2002) An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3, 1169–1176

2. Serwold, T., Gonzalez, F., Kim, J., Jacob, R., and Shastri, N. (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480–483

3. Hammer, G. E., Gonzalez, F., Champsaur, M., Cado, D., and Shastri, N. (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat. Immunol. 7, 103–112

4. Hammer, G. E., Gonzalez, F., James, E., Nolla, H., and Shastri, N. (2007) In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat. Immunol. 8, 101–108

5. Yan, J., Parekh, V. V., Mendez-Fernandez, Y., Olivares-Villagomez, D., Dragovic, S., Hill, T., Roopenian, D. C., Joyce, S., and Van Kaer, L. (2006) In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class I and class IIb molecules. J. Exp. Med. 203, 647–659

6. Blanchard, N., Kanaseki, T., Escobar, H., Delebecque, F., Nagarajan, N. A., Revesz,Vargas, E., Crockett, D. K., Rauet, D. H., Delgado, J. C., and Shastri, N. (2010) Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells. J. Immunol. 184, 3033–3042

7. Chen, L., Fischer, R., Peng, Y., Reeves, E., McLugh, K., Ternette, N., Hanke, T., Dong, T., Elliott, T., Shastri, N., Kollberger, S., James, E., Kostulas, B., and Bownness, P. (2014) Critical Role of Endoplasmic Reticulum Aminopeptidase 1 in Determining the Length and Sequence of Peptides Bound and Presented by HLA-B*27. Arthritis Rheumatol. 66, 284–294

8. Barnea, E., Melamed, K. D., Haimovich, Y., Satmuri, N., Dorris, M. L., Nguyen, M. T., Hammer, R. E., Tran, T. M., Colbert, R. A., Taurog, J. D., and Admon, A. (2017) The HLA-B*27 peptidome in vivo in spondyloarthritis-susceptible HLA-B27 transgenic rats and the effect of ERAP1 deletion. Mol. Cell Proteomics 16, 642–662

9. Serwold, T., Gaw, S., and Shastri, N. (2001) ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat. Immunol. 2, 644–651

10. Saveanu, L., Carroll, O., Lindo, V., Del Val, M., Lopez, D., Lepelletier, Y., Greer, F., Schomburg, L., Fruci, D., Niedermann, G., and Van Endert, P. M. (2005) Concerted peptide trimming by human ERAp1 and ERAp2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6, 689–697

11. Goto, Y., Tanji, H., Hattori, A., and Tsujimoto, M. (2008) Glutamin-181 is crucial in the enzymatic activity and substrate specificity of human endoplasmic-reticulum aminopeptidase-1. Biochem. J. 416, 109–116

12. Hearn, A., York, I. A., and Rock, K. L. (2009) The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J. Immunol. 183, 5526–5536

13. Chang, S. C., Momburg, F., Bhatnami, N., and Goldberg, A. L. (2005) The ER aminopeptidase ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc. Natl. Acad. Sci. U.S.A. 102, 17107–17112

14. Ombrello, M. J., Kastner, D. L., and Remmers, E. F. (2015) Endoplasmic reticulum-associated aminopeptidase 1 and rheumatic disease: genet- ics, structure, and function. Arthritis Res. Ther. 17, 284–294

15. WTCC Consortium. (2007) Association scan of 14,500 nonsynonymous single nucleotide polymorphisms in 4,897 rheumatoid arthritis cases and 4,905 controls. Nat. Genet. 39, 1329–1337

16. The TASK and WTCCC2 Consortia. (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761–767

17. Strange, A., Capon, F., Spencer, C. C., Knight, J., Weale, M. E., Allen, M. H., Barton, A., Band, G., Bellenguez, C., Berpoer, J. G., Blackwell, J. M., Bramon, E., Bumpstead, S. J., Casas, J. P., Cork, M. J., Corvin, A., Deloukas, P., Dilthey, A., Duncanson, A., Edkins, S., Estivill, X., Fitzger- ald, O., Freeman, C., Giardina, E., Gray, E., Hofer, A., Huffmeier, U., Hunt, S. E., Irvine, A. D., Jankowski, J., Kirby, B., Langford, C., Laszcorz, J., Leman, J., Leslie, S., Malbriris, L., Markus, H. S., Mathew, C. G., McLean, W. H., McManus, R., Mounser, H., Mourtin, L., Nalauu, A. T., Nestle, O., Pirinen, M., Plomin, R., Potter, S. C., Pujol, R. M., Rautanen, A., Riveira-Munoz, E., Ryan, A. W., Salmhofer, W., Samuelsson, L., Sawyer, S. J., Schalkwijk, J., Smith, C. H., Stahlé, M., Su, Z., Tazi-Ahnini, R., Traupe, H., Viswanathan, A. C., Warren, R. B., Weger, W., Wolk, K., Wood, N.,
ERAP1 Polymorphism and the HLA-B*27 Peptidome

Worthington, J., Young, H. S., Zeeuwen, P. L., Hayday, A., Burden, A. D., Griffiths, C. E., Kere, J., Reis, A. M., McVean, G., Evans, D. M., Brown, M. A., Barker, J. N., Peltonen, L., Donnelly, P., and Trombath, R. C. (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat. Genet.* 42, 985–990

18. Kirino, Y., Bertias, G., Ishigatsubo, Y., Mizuki, N., Tugal-Tutkun, I., Seyei, E., Ozuyazgan, Y., Sacil, F. S., Eger, B., Inoko, H., Emrence, Z., Cakar, A., Abaci, N., Udest, D., Satorius, C., Ueda, A., Takeno, M., Kim, Y., Wood, G. M., Ombrello, M. J., Meguro, A., Gul, A., Remmers, E. F., and Kastner, D. L. (2013) Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B*51 and ERAP1. *Nat. Genet.* 45, 202–207

19. Hanson, A. L., Cuddihy, T., Haynes, K., Loo, D., Morton, C. J., Oppermann, U., Levine, Thomas, G. P., Le Cao, K. A., Kenna, T. J., and Brown, M. A. (2018) Genetic variants in ERAP1 and ERAP2 associated with immune-mediated diseases influence protein expression and isoform profile. *Arthritis Rheumatol.* 70, 255–265

20. Harvey, D., Pointon, J. J., Evans, D. M., Karaderi, T., Farrar, C., Appleton, L. H., Sturrock, R. D., Stone, M. A., Oppermann, U., Brown, M. A., and Wordsworth, B. P. (2009) Investigating the genetic association between HLA-B27 and ankylosing spondylitis. *Hum. Mol. Genet.* 18, 4204–4212

21. van de Bunt, M., Cortes, A., IGAS Consortium, Brown, M. A., Morris, A. P., and McCarthy, M. I. (2015) Evaluating the Performance of Fine-Mapping Strategies at Common Variant GWAS Loci. *PLoS Genet.* 11, e1005535

22. Lopez de Castro, J. A., Alvarez-Navarro, C., Brito, A., Guasp, P., Martin-Esteban, A., and Sanz-Bravo, A. (2016) Molecular and pathogenic effects of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in MHC-I-associated inflammatory disorders: Towards a unifying view. *Mol. Immunol.* 77, 193–204

23. Martin-Esteban, A., Gomez-Molina, P., Sanz-Bravo, A., and Lopez de Castro, J. A. (2014) Combined Effects of Ankylosing Spondylitis-associated ERAP1 Polymorphisms Outside the Catalytic and Peptide-binding Sites on the Processing of Natural HLA-B27 Ligands. *J. Biol. Chem.* 289, 3978–3990

24. Reeves, E., Edwards, C. J., Elliott, T., and James, E. (2013) Naturally Occurring ERAP1 Haplotypes Encode Functionally Distinct Alleles with Fine Substrate Specificity. *J. Immunol.* 191, 35–43

25. Garcia-Medel, N., Sanz-Bravo, A., Van Nguyen, D., Galocha, B., Gomez-Molina, P., Martin-Esteban, A., Alvarez-Navarro, C., and Lopez de Castro, J. A. (2012) Functional Interaction of the Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 1 Polymorphism and HLA-B27 in Vivo. *Mol. Cell. Proteomics.* 11, 1416–1429

26. Sanz-Bravo, A., Caro, J., Mazarrigos, M. S., and Lopez de Castro, J. A. (2015) Dominant Role of the ERAP1 Polymorphism R528K in Shaping the HLA-B27 Peptidome Through Differential Processing Determined by Multiple Peptide Residues. *Arthritis Rheumatol.* 67, 892–701

27. Goto, Y., Hattori, A., Ishii, Y., and Tsujimoto, M. (2006) Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1. *N. Engl. J. Med.* 354, 1833–1838

28. Evnouchidou, I., Weimershaus, M., Saveanu, L., and van Endert, P. (2014) ERAP1–ERAP2 Dimerization Increases Peptide-Trimming Efficiency. *J. Immunol.* 193, 901–908

29. Chen, H., Li, L., Weimershaus, M., Evnouchidou, I., van Endert, P., and Bouvier, M. (2016) ERAP1–ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing. *Sci. Rep.* 6, 29902

30. Andres, A. M., Dennis, M. Y., Kretzschmar, W. W., Cannons, J. L., Lee-Lin, S. Q., Hurie, B., Schwartzberg, P. L., Williamson, S. H., Bustamante, C. D., Nielsen, R., Clark, A. G., and Green, E. D. (2010) Balancing selection maintains a form of ERAP2 that undergoes non-sense-mediated decay and affects antigen presentation. *PLoS Genet.* 6, e1001157

31. Martin-Esteban, A., Guasp, P., Barnea, E., Admon, A., and Lopez de Castro, J. A. (2016) Functional Interaction of the Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase 2 with the HLA-B*27 Peptidome in Human Cells. *Arthritis Rheumatol.* 68, 2466–2475

32. Martin-Esteban, A., Sanz-Bravo, A., Guasp, P., Barnea, E., Admon, A., and Lopez de Castro, J. A. (2017) Separate effects of the ankylosing spondylitis-associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome. *J. Autoimmun.* 79, 28–38

33. Zemmour, J., Little, A. M., Schendel, D. J., and Parham, P. (1992) The HLA-A,B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. *J. Immunol.* 141, 1941–1948

34. Bertsias, G., Ishigatsubo, Y., Mizuki, N., Tugal-Tutkun, I., Seyahi, E., Ozuyazgan, Y., Sacil, F. S., Eger, B., Inoko, H., Emrence, Z., Cakar, A., Abaci, N., Udest, D., Satorius, C., Ueda, A., Takeno, M., Kim, Y., Wood, G. M., Ombrello, M. J., Meguro, A., Gul, A., Remmers, E. F., and Kastner, D. L. (2013) Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B*51 and ERAP1. *Nat. Genet.* 45, 202–207

35. Hanson, A. L., Cuddihy, T., Haynes, K., Loo, D., Morton, C. J., Oppermann, U., Levine, Thomas, G. P., Le Cao, K. A., Kenna, T. J., and Brown, M. A. (2018) Genetic variants in ERAP1 and ERAP2 associated with immune-mediated diseases influence protein expression and isoform profile. *Arthritis Rheumatol.* 70, 255–265

36. Harvey, D., Pointon, J. J., Evans, D. M., Karaderi, T., Farrar, C., Appleton, L. H., Sturrock, R. D., Stone, M. A., Oppermann, U., Brown, M. A., and Wordsworth, B. P. (2009) Investigating the genetic association between HLA-B27 and ankylosing spondylitis. *Hum. Mol. Genet.* 18, 4204–4212

37. Goto, Y., Hattori, A., Voulgari, P. V., Drosos, A. A., Amalfitano, A., York, I. A., and Tsujimoto, M. (2006) Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1. *N. Engl. J. Med.* 354, 1833–1838

38. Evnouchidou, I., Weimershaus, M., Saveanu, L., and van Endert, P. (2014) ERAP1–ERAP2 Dimerization Increases Peptide-Trimming Efficiency. *J. Immunol.* 193, 901–908

39. Chen, H., Li, L., Weimershaus, M., Evnouchidou, I., van Endert, P., and Bouvier, M. (2016) ERAP1–ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing. *Sci. Rep.* 6, 29902
51. Mobbs, J. I., Illing, P. T., Dudek, N. L., Brooks, A. G., Baker, D. G., Purcell, A. W., Rossjohn, J., and Vivian, J. P. (2017) The molecular basis for peptide repertoire selection in the human leucocyte antigen (HLA) C*06:02 molecule. J. Biol. Chem. 292, 17203–17215
52. Takeuchi, M., Ombrello, M. J., Kirino, Y., Erer, B., Tugal-Tutkun, I., Seyahi, E., Ozyazgan, Y., Watts, N. R., Gul, A., Kastner, D. L., and Remmers, E. F. (2017) A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behcet’s disease in HLA-B*51 carriers. Ann. Rheum. Dis. 75, 2208–2211
53. Guasp, P., Barnea, E., Gonzalez-Escribano, M. F., Jimenez-Reinoso, A., Regueiro, J. R., Admon, A., and Lopez de Castro, J. A. (2017) The Behcet’s disease-associated variant of the aminopeptidase ERAP1 shapes a low affinity HLA-B*51 peptidome by differential subpeptidome processing. J. Biol. Chem. 292, 9680–9689